Trial Profile

A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Accelerated Phase

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olverembatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Registrational; Therapeutic Use
Sponsors Ascentage Pharma

Most Recent Events

06 Nov 2024 According to an Ascendis Pharma media release, this Olverembatinib trial have been selected for presentation, at the 66th American Society of Hematology (ASH) Annual Meeting.
13 Dec 2022 Updated results of pivotal Phase 2 trials(HQP1351-CC-201 and HQP1351-CC-202) presented at the 64th American Society of Hematology Annual Meeting and Exposition.
11 Dec 2022 Results published in an Ascendis Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com